Nonbenzodiazepine hypnotics and police-reported motor vehicle crash risk among older adults: a sequential target trial emulation
- 2 July 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (3) , 662-673
Abstract
Nonbenzodiazepine hypnotics (“Z-drugs”) are prescribed for insomnia but might increase the risk of motor vehicle crash (MVC) among older adults through prolonged drowsiness and delayed reaction times. We estimated the effect of initiating Z-drug treatment on the 12-week risk of MVC in a sequential target trial emulation. After linking New Jersey driver licensing and police-reported MVC data to Medicare claims, we emulated a new target trial each week (July 1, 2007, to October 7, 2017) in which Medicare fee-for-service beneficiaries were classified as Z-drug-treated or untreated at baseline and followed for an MVC. We used inverse probability of treatment and censoring-weighted pooled logistic regression models to estimate risk ratios (RRs) and risk differences with 95% bootstrap confidence limits (CLs). There were 257 554 person-trials, of which 103 371 were Z-drug-treated and 154 183 untreated, giving rise to 976 and 1249 MVCs, respectively. The intention-to-treat RR was 1.06 (95% CL, 0.95-1.16). For the per-protocol estimand, there were 800 MVCs and 1241 MVCs among treated and untreated person-trials, respectively, suggesting a reduced MVC risk (RR, 0.83; 95% CL, 0.74-0.92) with sustained Z-drug treatment. Z-drugs should be prescribed to older patients judiciously but not withheld entirely over concerns about MVC risk. This article is part of a Special Collection on Pharmacoepidemiology.Keywords
Funding Information
- National Institute on Aging (R01AG079295, R21AG061632)
- National Institute on Aging (R01AG065722)
This publication has 80 references indexed in Scilit:
- High‐dimensional propensity scores for empirical covariate selection in secondary database studies: Planning, implementation, and reportingPharmacoepidemiology and Drug Safety, 2022
- Driving performance and neurocognitive skills of long‐term users of benzodiazepine anxiolytics and hypnoticsHuman Psychopharmacology: Clinical and Experimental, 2019
- Variable selection on large case-crossover data: application to a registry-based study of prescription drugs and road traffic crashesPharmacoepidemiology and Drug Safety, 2013
- Differential effects of diazepam, tandospirone, and paroxetine on plasma brain‐derived neurotrophic factor level under mental stressHuman Psychopharmacology: Clinical and Experimental, 2012
- Index Event Bias as an Explanation for the Paradoxes of Recurrence Risk ResearchJAMA, 2011
- The effects of acute treatment with tandospirone, diazepam, and placebo on driving performance and cognitive function in healthy volunteersHuman Psychopharmacology: Clinical and Experimental, 2010
- Effects of prolonged‐release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteersHuman Psychopharmacology: Clinical and Experimental, 2008
- Methods for testing impairment of driving due to drugsEuropean Journal of Clinical Pharmacology, 1992
- Psychomotor performance and real driving performance of outpatients receiving diazepamPsychopharmacology, 1981
- Effects of diazepam and codeine, alone and in combination with alcohol, on simulated drivingClinical Pharmacology & Therapeutics, 1974